Boehringer Ingelheim And Zhejiang Hisoar Pharmaceutical Sign Production Alliance
This article was originally published in PharmAsia News
Executive Summary
Boehringer Ingelheim and Zhejiang Hisoar Pharmaceutical have signed a strategic production alliance. Under the agreement, Hisoar will invest in a specialized workshop at its new plant in Chuannan and is scheduled to manufacture contract products for BI from 2009. The latter on its part will provide expertise and technology support for Hisoar. Listed on the Shenzhen bourse in 2006, Hisoar specializes in producing and selling pharmaceutical chemicals, active pharmaceutical ingredients and generic drugs. It has established GMP and EHS systems according to international standards. The firm said that the BI collaboration will boost its market position and influence, as well as give it a major leg-up toward globalization
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.